From One Receptor to Three: How Target Count Tracks With Weight-Loss Results Across Three Trials
-14.9% Against -2.4%: What STEP 1 Reported in 2021
Semaglutide acts on a single target, the GLP-1 receptor. In the STEP 1 trial, published in 2021, the trial found a mean weight change of -14.9% over 68 weeks, compared with -2.4% on placebo over the same 68 weeks.
That single-receptor result became a reference point for later trials testing drugs built to hit more than one hormone pathway at once.
Semaglutide is a prescription-only medicine in Australia, as most peptides are, and its approved uses are set out in its product information rather than in any single trial result.
Adding a Second Target: SURMOUNT-1 and GIP
Tirzepatide was built to act on two receptors, GLP-1 and GIP, rather than one. In SURMOUNT-1, a 2022 trial, the trial found that its highest dose arm reached a mean weight change of -20.9% over 72 weeks, against -3.1% on placebo.
The trial ran four weeks longer than STEP 1 and enrolled a different participant group, so the gap between -20.9% and -14.9% cannot be read as a clean effect of adding the GIP target alone.
Trial length, baseline body weight, and enrolment criteria all shift mean results, and SURMOUNT-1 differed from STEP 1 on all three counts.
Three Receptors, 48 Weeks: The Retatrutide Phase 2 Numbers
Retatrutide goes further again, acting on GLP-1, GIP and glucagon receptors. In its 2023 phase 2 trial, the trial found that the highest dose arm reached a mean weight change of -24.2% over 48 weeks, against -2.1% on placebo.
This result came from a shorter trial than either STEP 1 or SURMOUNT-1, which matters because weight change in these trials tends to continue accruing over time rather than plateauing early.
A phase 2 trial is also smaller and earlier in the regulatory process than the phase 3 trials behind STEP 1 and SURMOUNT-1, so its numbers carry a different evidentiary weight.
Why Three Numbers in a Row Are Not a Ranking
Lined up, the three placebo-adjusted gaps look like a staircase: one receptor at -14.9%, two receptors at -20.9%, three receptors at -24.2%. But STEP 1, SURMOUNT-1 and the retatrutide phase 2 trial ran for different durations, recruited different participants, and used different trial designs, so the figures sit side by side without being a head-to-head comparison.
The TGA states that approval decisions rest on the full evidence package submitted for a specific product and its specific proposed use, not on cross-trial comparisons of percentages from separate studies.
Readers comparing these numbers should treat trial length and participant selection as variables as important as the number of receptors a molecule engages.
What Changes When a Committee Reviews These Results
When a regulatory committee assesses a new multi-receptor peptide, it weighs the trial design alongside the headline percentage. A committee voted on tirzepatide's approved indications only after reviewing the full SURMOUNT-1 dataset, not the single -20.9% figure in isolation.
The practical lesson is to read trial length and placebo gap together, not the top-line number alone, before drawing conclusions about what a receptor target adds.
Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.
Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (New England Journal of Medicine, 2021)
- Tirzepatide Once Weekly for the Treatment of Obesity (New England Journal of Medicine, 2022)
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (New England Journal of Medicine, 2023)